JP Morgan Chase
BBIO icon

JP Morgan Chase’s BridgeBio Pharma BBIO Stock Holding History

JP Morgan Chase’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$153K Hold
2,200
– – ﹤0.01% 5612
2025
Q4 		$168K Sell
2,200
-10,900
-83% -$715K ﹤0.01% 5623
2025
Q3 		$680K Sell
13,100
-27,200
-67% -$1.33M ﹤0.01% 4847
2025
Q2 		$1.74M Sell
40,300
-31,500
-44% -$1.15M ﹤0.01% 4017
2025
Q1 		$2.48M Buy
71,800
+21,200
+42% +$715K ﹤0.01% 3712
2024
Q4 		$1.39M Buy
+50,600
New +$1.31M ﹤0.01% 4394
2024
Q3 		– Sell
-16,100
Closed -$408K – 7410
2024
Q2 		$408K Sell
16,100
-30,800
-66% -$842K ﹤0.01% 4795
2024
Q1 		$1.45M Buy
46,900
+29,000
+162% +$986K ﹤0.01% 4080
2023
Q4 		$723K Buy
+17,900
New +$538K ﹤0.01% 4550
2023
Q3 		– Sell
-9,100
Closed -$157K – 7459
2023
Q2 		$157K Sell
9,100
-9,500
-51% -$143K ﹤0.01% 5223
2023
Q1 		$308K Buy
+18,600
New +$217K ﹤0.01% 4793
2022
Q1 		– Sell
-60,000
Closed -$1M – 6587
2021
Q4 		$1M Buy
+60,000
New +$2.54M ﹤0.01% 4380

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase's BBIO Position: Q1 2026 in Review

JP Morgan Chase increased its BridgeBio Pharma (BBIO) stake by 53% in Q1 2026, buying an estimated $32.9M and bringing the position to 1,312,259 shares worth $91M. The position accounts for 0.01% of the portfolio, ranked #1041.

JP Morgan Chase first reported a position in BBIO in Q2 2019 and has held it in 28 quarters since. The position peaked at $98.3M in Q2 2021. 458 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • JP Morgan Chase held 1,312,259 shares of BridgeBio Pharma worth $91M as of Q1 2026.
  • JP Morgan Chase bought 453,291 BridgeBio Pharma shares in Q1 2026, an estimated $32.9M.
  • BridgeBio Pharma made up 0.01% of JP Morgan Chase's portfolio in Q1 2026, its #1041 holding.
  • JP Morgan Chase first reported a position in BridgeBio Pharma in Q2 2019 and has held it in 28 quarters since.
  • JP Morgan Chase's BridgeBio Pharma position peaked at $98.3M in Q2 2021.
  • 458 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.